|Healthcare Review: Heron Therapeutics, Bruker Corp, Surgical, Shire, Aerie Pharmaceuticals|
|By Staff and Wire Reports|
|Wednesday, 25 June 2014 14:11|
Heron Therapeutics ($HRTX) prices its public offering of 4.5M shares of common stock at $11.75 per share. Underwriters over-allotment is 675K shares. Gross proceeds will be ~$60M (assumes full exercise of over-allotment). Net proceeds will be used for general corporate purposes including funding ongoing and future clinical trials. Closing date is June 30.A component of the deal is the offering of pre-funded warrants to certain existing large shareholders at a price of $11.74 per warrant to purchase an aggregate of 600K shares of common stock.
The China Food and Drug Administration clears Bruker Corp's ($BRKR) MALDI Biotyper System for sale in China. The system's matrix assisted laser desorption ionization-time of flight mass spectrometer identifies microorganisms by measuring their molecular fingerprints and comparing them to a reference library of more than 2,300 species of gram-negative and gram-positive bacteria, anaerobes and yeasts.
Following April's FDA approval, Intuitive Surgical's ($ISRG) da Vinci Xi surgical system gets CE Mark clearance in Europe. The new system is optimized for four-quadrant surgery. It enables efficient access through out the pelvis, abdomen and chest and incorporates enhanced ease-of-use features.
The U.S. District Court of New Jersey finds that Shire's ($SHPG) patents protecting ADHD drug Vyvanse (lisdexamfetamine dimesylate) are both infringed and valid in a lawsuit against five would-be generic competitors. The patents are valid until 2023. In order to launch their competing offerings, the generic firms must overturn each of the 18 patent claims (from four Orange Book-listed patents) on appeal.
Shares of Aerie Pharmaceuticals ($AERI) are up 23% in response to its announcement of successful results for its glaucoma drug candidate Roclatan in a 297-patient 28-day Phase 2b clinical trial. Roclatan is a combination of the company's triple-action Rhopressa and latanoprost, a prostaglandin analogue that is the most widely prescribed glaucoma drug.